De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!
Fulgent Genetics Inkomsten in het verleden
Verleden criteriumcontroles 0/6
De winst van Fulgent Genetics is gedaald met een gemiddeld jaarlijks percentage van -17.2%, terwijl de winst van de Healthcare -industrie jaarlijks groeide met 6.2%. De inkomsten zijn groeide met een gemiddeld percentage van 14.1% per jaar.
Belangrijke informatie
-17.2%
Groei van de winst
-18.0%
Groei van de winst per aandeel
| Healthcare Groei van de industrie | 8.5% |
| Inkomstengroei | 14.1% |
| Rendement op eigen vermogen | -15.1% |
| Nettomarge | -56.2% |
| Laatste winstupdate | 30 Jun 2024 |
Recente prestatie-updates uit het verleden
Recent updates
Fulgent Genetics: An NCAV Pick With Profit And Growth Potential
Sep 25Fulgent Genetics: Core Growth Re-Acceleration Will Be The Critical Catalyst
Sep 09Some Shareholders Feeling Restless Over Fulgent Genetics, Inc.'s (NASDAQ:FLGT) P/S Ratio
Jul 17
Fulgent Genetics: Growth Is Returning
Jun 06Shareholders May Be Wary Of Increasing Fulgent Genetics, Inc.'s (NASDAQ:FLGT) CEO Compensation Package
May 10Analysts Have Been Trimming Their Fulgent Genetics, Inc. (NASDAQ:FLGT) Price Target After Its Latest Report
May 07Are Investors Undervaluing Fulgent Genetics, Inc. (NASDAQ:FLGT) By 32%?
Mar 01Fulgent Genetics: Buy Growth Ahead Below Liquidation Value
Feb 21Subdued Growth No Barrier To Fulgent Genetics, Inc.'s (NASDAQ:FLGT) Price
Jan 17Is Fulgent Genetics (NASDAQ:FLGT) Using Debt Sensibly?
Dec 14Fulgent Genetics (NASDAQ:FLGT) Has Debt But No Earnings; Should You Worry?
Aug 09Analysts Have Been Trimming Their Fulgent Genetics, Inc. (NASDAQ:FLGT) Price Target After Its Latest Report
May 09Fulgent Genetics (NASDAQ:FLGT) Is Looking To Continue Growing Its Returns On Capital
Apr 19Why We Like The Returns At Fulgent Genetics (NASDAQ:FLGT)
Jan 15Does Fulgent Genetics (NASDAQ:FLGT) Have A Healthy Balance Sheet?
Dec 28What Does The Future Hold For Fulgent Genetics, Inc. (NASDAQ:FLGT)? These Analysts Have Been Cutting Their Estimates
Nov 16Why Fulgent Genetics, Inc. (NASDAQ:FLGT) Could Be Worth Watching
Oct 27Wait For Fulgent Genetics To Grow Up
Oct 13We Like Fulgent Genetics' (NASDAQ:FLGT) Returns And Here's How They're Trending
Sep 19Fulgent Genetics (NASDAQ:FLGT) Seems To Use Debt Rather Sparingly
Sep 05Fulgent Genetics: Poised To Survive Its Post-Covid Hangover
Jul 26Fulgent Genetics, Inc.'s (NASDAQ:FLGT) Low P/E No Reason For Excitement
Jul 21Fulgent Genetics (NASDAQ:FLGT) Is Investing Its Capital With Increasing Efficiency
Jun 04Fulgent Is Putting Its Cash Bonanza To Work
May 15These 4 Measures Indicate That Fulgent Genetics (NASDAQ:FLGT) Is Using Debt Safely
May 04Fulgent Genetics: Now The Going Could Get Much Tougher
Apr 10Fulgent Genetics: COVID Bolstered The Underlying Business
Mar 17Fulgent Genetics: Somewhat Disappoints With A Marked Slowdown In Its NGS Business
Feb 27Fulgent Genetics Stock: 35% Off Its Recent Highs - It Is Now A Buy
Feb 09Fulgent Genetics: Sell Volatility
Jan 26Fulgent Genetics (NASDAQ:FLGT) Has A Rock Solid Balance Sheet
Jan 25Opbrengsten en kosten
Hoe Fulgent Genetics geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
| Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
|---|---|---|---|---|
| 30 Jun 24 | 291 | -163 | 128 | 47 |
| 31 Mar 24 | 288 | -166 | 126 | 43 |
| 31 Dec 23 | 289 | -168 | 128 | 41 |
| 30 Sep 23 | 286 | -64 | 113 | 38 |
| 30 Jun 23 | 307 | -49 | 135 | 35 |
| 31 Mar 23 | 365 | -26 | 142 | 33 |
| 31 Dec 22 | 619 | 143 | 144 | 29 |
| 30 Sep 22 | 803 | 272 | 141 | 28 |
| 30 Jun 22 | 925 | 392 | 118 | 26 |
| 31 Mar 22 | 953 | 461 | 96 | 25 |
| 31 Dec 21 | 993 | 507 | 75 | 24 |
| 30 Sep 21 | 1,036 | 569 | 58 | 21 |
| 30 Jun 21 | 910 | 493 | 48 | 18 |
| 31 Mar 21 | 773 | 417 | 40 | 15 |
| 31 Dec 20 | 422 | 214 | 30 | 12 |
| 30 Sep 20 | 135 | 48 | 21 | 9 |
| 30 Jun 20 | 44 | 3 | 15 | 7 |
| 31 Mar 20 | 35 | 0 | 13 | 7 |
| 31 Dec 19 | 33 | 0 | 12 | 7 |
| 30 Sep 19 | 30 | -2 | 11 | 6 |
| 30 Jun 19 | 25 | -4 | 11 | 6 |
| 31 Mar 19 | 22 | -6 | 10 | 6 |
| 31 Dec 18 | 21 | -6 | 10 | 6 |
| 30 Sep 18 | 20 | -5 | 10 | 5 |
| 30 Jun 18 | 19 | -6 | 10 | 5 |
| 31 Mar 18 | 18 | -5 | 10 | 5 |
| 31 Dec 17 | 19 | -3 | 9 | 4 |
| 30 Sep 17 | 20 | 0 | 9 | 4 |
| 30 Jun 17 | 21 | -5 | 8 | 4 |
| 31 Mar 17 | 20 | -13 | 7 | 4 |
| 31 Dec 16 | 18 | -14 | 7 | 4 |
| 30 Sep 16 | 15 | -22 | 9 | 6 |
| 30 Jun 16 | 13 | -15 | 7 | 5 |
| 31 Mar 16 | 11 | -6 | 7 | 5 |
| 31 Dec 15 | 10 | -5 | 5 | 4 |
| 31 Dec 14 | 1 | -1 | 1 | 1 |
Kwaliteitswinsten: FLGT is momenteel verliesgevend.
Groeiende winstmarge: FLGT is momenteel verliesgevend.
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: FLGT is verliesgevend en de verliezen zijn de afgelopen 5 jaar toegenomen met een snelheid van 17.2% per jaar.
Versnelling van de groei: Het is niet mogelijk om de winstgroei van FLGT over het afgelopen jaar te vergelijken met het gemiddelde over de afgelopen vijf jaar, omdat het bedrijf momenteel verliesgevend is.
Winst versus industrie: FLGT is verlieslatend, waardoor het lastig is om de winstgroei van het afgelopen jaar te vergelijken met die van de Healthcare industrie ( 8% ).
Rendement op eigen vermogen
Hoge ROE: FLGT heeft een negatief Return on Equity ( -15.12% ), omdat het momenteel verliesgevend is.